Final Results of ABCSG-24, a Randomized Phase III Study Comparing Epirubicin, Docetaxel, and Capecitabine (EDC) to Epirubicin and Docetaxel (ED) as Neoadjuvant Treatment for Early Breast Cancer and Comparing ED/EDC plus Trastuzumab (T) to ED/EDC as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer

GG Steger; Richard Greil; R Jakesz; A Lang; B Mlineritsch; E Melbinger-Zeinitzer; C Marth; H Samonigg; E Kubista; M Gnant

Final Results of ABCSG-24, a Randomized Phase III Study Comparing Epirubicin, Docetaxel, and Capecitabine (EDC) to Epirubicin and Docetaxel (ED) as Neoadjuvant Treatment for Early Breast Cancer and Comparing ED/EDC plus Trastuzumab (T) to ED/EDC as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer

GG Steger
, Richard Greil
, R Jakesz
, A Lang
, B Mlineritsch
, E Melbinger-Zeinitzer
, C Marth
, H Samonigg
, E Kubista
, M Gnant

Department of Internal Medicine III - Division of Hematology, Medical Oncology, Hemostaseology, Rheumatology, Infectiology and Oncologic Center

Research output: Contribution to journal › Abstract (Journal) › peer-review

4 Citations (Web of Science)

Original language	English
Pages (from-to)	564S-564S
Journal	CANCER RESEARCH
Volume	69
Issue number	24
Publication status	Published - 2009
Event	32nd Annual San Antonio Breast Cancer Symposium - San Antonio, TX Duration: 9 Dec 2009 → 13 Dec 2009

Cite this

Steger, GG., Greil, R., Jakesz, R., Lang, A., Mlineritsch, B., Melbinger-Zeinitzer, E., Marth, C., Samonigg, H., Kubista, E., & Gnant, M. (2009). Final Results of ABCSG-24, a Randomized Phase III Study Comparing Epirubicin, Docetaxel, and Capecitabine (EDC) to Epirubicin and Docetaxel (ED) as Neoadjuvant Treatment for Early Breast Cancer and Comparing ED/EDC plus Trastuzumab (T) to ED/EDC as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer. CANCER RESEARCH , 69(24), 564S-564S.

Steger, GG ; Greil, Richard ; Jakesz, R et al. / Final Results of ABCSG-24, a Randomized Phase III Study Comparing Epirubicin, Docetaxel, and Capecitabine (EDC) to Epirubicin and Docetaxel (ED) as Neoadjuvant Treatment for Early Breast Cancer and Comparing ED/EDC plus Trastuzumab (T) to ED/EDC as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer. In: CANCER RESEARCH 2009 ; Vol. 69, No. 24. pp. 564S-564S.

@article{dfbc657a1e924d4484ff19107747490c,

title = "Final Results of ABCSG-24, a Randomized Phase III Study Comparing Epirubicin, Docetaxel, and Capecitabine (EDC) to Epirubicin and Docetaxel (ED) as Neoadjuvant Treatment for Early Breast Cancer and Comparing ED/EDC plus Trastuzumab (T) to ED/EDC as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer",

author = "GG Steger and Richard Greil and R Jakesz and A Lang and B Mlineritsch and E Melbinger-Zeinitzer and C Marth and H Samonigg and E Kubista and M Gnant",

year = "2009",

language = "English",

volume = "69",

pages = "564S--564S",

journal = "CANCER RESEARCH ",

issn = "0008-5472",

publisher = "Amer Assoc Cancer Research",

number = "24",

note = "32nd Annual San Antonio Breast Cancer Symposium ; Conference date: 09-12-2009 Through 13-12-2009",

}

Steger, GG, Greil, R, Jakesz, R, Lang, A, Mlineritsch, B, Melbinger-Zeinitzer, E, Marth, C, Samonigg, H, Kubista, E & Gnant, M 2009, 'Final Results of ABCSG-24, a Randomized Phase III Study Comparing Epirubicin, Docetaxel, and Capecitabine (EDC) to Epirubicin and Docetaxel (ED) as Neoadjuvant Treatment for Early Breast Cancer and Comparing ED/EDC plus Trastuzumab (T) to ED/EDC as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer', CANCER RESEARCH , vol. 69, no. 24, pp. 564S-564S.

Final Results of ABCSG-24, a Randomized Phase III Study Comparing Epirubicin, Docetaxel, and Capecitabine (EDC) to Epirubicin and Docetaxel (ED) as Neoadjuvant Treatment for Early Breast Cancer and Comparing ED/EDC plus Trastuzumab (T) to ED/EDC as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer. / Steger, GG; Greil, Richard; Jakesz, R et al.
In: CANCER RESEARCH , Vol. 69, No. 24, 2009, p. 564S-564S.

Research output: Contribution to journal › Abstract (Journal) › peer-review

TY - JOUR

T1 - Final Results of ABCSG-24, a Randomized Phase III Study Comparing Epirubicin, Docetaxel, and Capecitabine (EDC) to Epirubicin and Docetaxel (ED) as Neoadjuvant Treatment for Early Breast Cancer and Comparing ED/EDC plus Trastuzumab (T) to ED/EDC as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer

AU - Steger, GG

AU - Greil, Richard

AU - Jakesz, R

AU - Lang, A

AU - Mlineritsch, B

AU - Melbinger-Zeinitzer, E

AU - Marth, C

AU - Samonigg, H

AU - Kubista, E

AU - Gnant, M

PY - 2009

Y1 - 2009

M3 - Abstract (Journal)

SN - 0008-5472

VL - 69

SP - 564S-564S

JO - CANCER RESEARCH

JF - CANCER RESEARCH

IS - 24

T2 - 32nd Annual San Antonio Breast Cancer Symposium

Y2 - 9 December 2009 through 13 December 2009

ER -

Steger GG, Greil R, Jakesz R, Lang A, Mlineritsch B, Melbinger-Zeinitzer E et al. Final Results of ABCSG-24, a Randomized Phase III Study Comparing Epirubicin, Docetaxel, and Capecitabine (EDC) to Epirubicin and Docetaxel (ED) as Neoadjuvant Treatment for Early Breast Cancer and Comparing ED/EDC plus Trastuzumab (T) to ED/EDC as Neoadjuvant Treatment for Early HER-2 Positive Breast Cancer. CANCER RESEARCH . 2009;69(24):564S-564S.